This 2023 retrospective study compared clomiphene citrate (CC) and enclomiphene citrate (EC) in treating male infertility and hypogonadism. Among 78 men (46 on EC, 32 on CC), both treatments significantly increased serum testosterone levels. However, only EC led to significant rises in FSH and LH levels and improved total motile
This 2015 case series evaluated 49 men with testosterone-induced azoospermia or severe oligospermia who underwent combination therapy with human chorionic gonadotropin (HCG) and adjunctive agents such as clomiphene citrate, tamoxifen, anastrozole, or recombinant follicle-stimulating hormone. Administered HCG at 3,000 IU subcutaneously every other day, the study observed a 95.9% recovery
This 2015 review addresses the challenge of managing hypogonadism in men desiring fertility preservation. Exogenous testosterone therapy can suppress the hypothalamic-pituitary-gonadal axis, leading to impaired spermatogenesis and potential azoospermia. The authors highlight alternative treatments, such as human chorionic gonadotropin (hCG), which can stimulate endogenous testosterone production and maintain intratesticular testosterone
This multi-institutional retrospective study compared the prevalence of secondary polycythemia in 363 hypogonadal men treated with either clomiphene citrate (CC) or testosterone replacement therapy (TRT). The study found that polycythemia occurred in 11.2% of men receiving TRT compared to only 1.7% in the CC group (p = 0.0003). Both treatments
This 1976 review examined 15 years of clinical experience using clomiphene citrate as an ovulation-inducing agent in over 2,000 patients. The findings indicated that the benefits of clomiphene therapy significantly outweighed its minor side effects, with a low incidence of serious birth defects comparable to that of the general population.
A population-based cohort study investigated the fetal safety of clomiphene citrate (CC) by assessing its association with major fetal malformations in 114,961 pregnant women, of whom 1,872 were exposed to CC. The study found no significant increase in the risk of major malformations, with an adjusted odds ratio of 1.08
Clomiphene citrate was evaluated in a study focused on its long-term safety and efficacy for treating hypogonadism, specifically in men with testosterone levels below 300 ng/dl. The study found significant improvements in testosterone levels and symptom relief, including reduced fatigue and increased libido, over extended periods (more than three years).
This comment, written by Saumya Pandey, addresses a previous study that examined the fetal safety of clomiphene citrate, a fertility treatment commonly used to induce ovulation. The original study, published in BJOG, evaluated the potential risks of clomiphene citrate exposure during pregnancy. Pandey’s commentary likely offers further insights or critiques
This study evaluated clomiphene citrate (CC) for safety in male patients with infertility or hypogonadism. Over 12 months, it found that CC significantly increased testosterone without affecting PSA or haematocrit levels. The study included 77 men aged 22-51, all treated with 50 mg daily or every other day. CC showed
The article on PubMed discusses the safety of Clomiphene Citrate, a fertility treatment. It provides an overview of the drug’s effectiveness and the potential risks associated with its use. The study highlights the safety profile, including side effects, and reassures clinicians about its use for women seeking treatment for infertility.
